奥拉巴里布促进了FABP4的表达,并减少了具有BRCA1突变的卵巢癌细胞中的抗瘤作用

奥拉巴里布促进了FABP4的表达,并减少了具有BRCA1突变的卵巢癌细胞中的抗瘤作用

相关实验视频

Updated: Jun 6, 2025

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.6K

Wei Huang¹, Hongxue Meng², Ye Xu¹

¹Department of Gynecological Oncology, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China.

Oncology letters

|December 2, 2024

概括

奥拉巴里布 (AZD2281) 在 BRCA 突变的卵巢癌 (OC) 中增加脂肪酸结合蛋白4 (FABP4),降低其有效性. 将olaparib与FABP4抑制剂结合使用可以增强抗瘤活性.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物化学生物化学

背景情况:

奥拉巴里布 (AZD2281) 是 BRCA 突变的卵巢癌 (OC) 的一线维持治疗.
脂肪酸结合蛋白4 (FABP4) 在Olaparib治疗BRCA突变的OC中的作用尚未完全理解.
澄清FABP4的功能可以提高OC治疗中的olaparib疗效.

研究的目的:

研究具有BRCA突变的OC细胞中FABP4的功能.
探索增强olaparib (AZD2281) 抗瘤功效的策略.

主要方法:

细胞计数套件-8,细胞亡,细胞循环和殖民地形成试验.
西部涂抹,RT-qPCR,ChIP,海马和ROS试验.
研究了AZD2281,FABP4过度表达/敲除以及与FABP4抑制剂BMS309403结合疗法的效果.

主要成果:

在COV362细胞中,AZD2281促进了亡和抑制了增殖,上调了CEBPα,PPARγ和FABP4.
过度表达FABP4降低了亡并促进了繁殖,而FABP4敲击则产生了相反的效果.
结合AZD2281和FABP4抑制剂BMS309403显著增强了亡并减少了殖民地形成.

结论:

AZD2281通过CEBPα-PPARγ上调FABP4,降低其在BRCA突变OC细胞中的抗瘤功效.
将AZD2281与FABP4抑制剂 (BMS309403) 结合在一起,为加强OC治疗提供了一个有前途的策略.
抑制FABP4可以克服耐药性并改善olaparib在BRCA突变卵巢癌中的治疗效果.

关键词:

BM S309403 的时间这是一种BRCA1突变.在FABP4中,FABP4是指FABP4.这就是Olaparib.卵巢癌是发生在卵巢的癌症.

更多相关视频

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.0K

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

08:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

14.6K

相关概念视频

02:57

Targeted Cancer Therapies

7.5K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.5K

02:23

Abnormal Proliferation

4.4K

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

4.4K

02:37

Restarting Stalled Replication Forks

5.7K

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...